Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models.

Chemoradiotherapy Humans Magnetic Resonance Imaging / methods Neoadjuvant Therapy / methods Precision Medicine Rectal Neoplasms / diagnostic imaging Reproducibility of Results Retrospective Studies Tomography, X-Ray Computed

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 06 2022
Historique:
received: 11 02 2022
accepted: 17 05 2022
entrez: 17 6 2022
pubmed: 18 6 2022
medline: 22 6 2022
Statut: epublish

Résumé

Radiomics analyses commonly apply imaging features of different complexity for the prediction of the endpoint of interest. However, the prognostic value of each feature class is generally unclear. Furthermore, many radiomics models lack independent external validation that is decisive for their clinical application. Therefore, in this manuscript we present two complementary studies. In our modelling study, we developed and validated different radiomics signatures for outcome prediction after neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC) based on computed tomography (CT) and T2-weighted (T2w) magnetic resonance (MR) imaging datasets of 4 independent institutions (training: 122, validation 68 patients). We compared different feature classes extracted from the gross tumour volume for the prognosis of tumour response and freedom from distant metastases (FFDM): morphological and first order (MFO) features, second order texture (SOT) features, and Laplacian of Gaussian (LoG) transformed intensity features. Analyses were performed for CT and MRI separately and combined. Model performance was assessed by the area under the curve (AUC) and the concordance index (CI) for tumour response and FFDM, respectively. Overall, intensity features of LoG transformed CT and MR imaging combined with clinical T stage (cT) showed the best performance for tumour response prediction, while SOT features showed good performance for FFDM in independent validation (AUC = 0.70, CI = 0.69). In our external validation study, we aimed to validate previously published radiomics signatures on our multicentre cohort. We identified relevant publications on comparable patient datasets through a literature search and applied the reported radiomics models to our dataset. Only one of the identified studies could be validated, indicating an overall lack of reproducibility and the need of further standardization of radiomics before clinical application.

Identifiants

DOI: 10.1038/s41598-022-13967-8 PMID: 35715462 PMC: PMC9205935
pubmed: 35715462
doi: 10.1038/s41598-022-13967-8
pii: 10.1038/s41598-022-13967-8
pmc: PMC9205935
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10192

Informations de copyright

© 2022. The Author(s).

Références

Thies, S. & Langer, R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front. Oncol. 3, 262 (2013).
pubmed: 24109590 pmcid: 3791673 doi: 10.3389/fonc.2013.00262
Dossa, F. et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2(7), 501–513 (2017).
pubmed: 28479372 doi: 10.1016/S2468-1253(17)30074-2
Chau, I. et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging—Defined poor-risk rectal cancer. J. Clin. Oncol. 24(4), 668–674 (2006).
pubmed: 16446339 doi: 10.1200/JCO.2005.04.4875
Rimkus, C. et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin. Gastroenterol. Hepatol. 6(1), 53–61 (2008).
pubmed: 18166477 doi: 10.1016/j.cgh.2007.10.022
Duldulao, M. P. et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis. Colon Rectum 56(2), 142 (2013).
pubmed: 23303141 pmcid: 4674069 doi: 10.1097/DCR.0b013e31827541e2
Boige, V. et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000–05. J. Clin. Oncol. 28(15), 2556–2564 (2010).
pubmed: 20385995 doi: 10.1200/JCO.2009.25.2106
Parmar, C. et al. Machine learning methods for quantitative radiomic biomarkers. Sci. Rep. 5(1), 1–11 (2015).
doi: 10.1038/srep13087
Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: Images are more than pictures, they are data. Radiology 278(2), 563–577 (2016).
pubmed: 26579733 doi: 10.1148/radiol.2015151169
Song, J. et al. A review of original articles published in the emerging field of radiomics. Eur. J. Radiol. 127, 108991 (2020).
pubmed: 32334372 doi: 10.1016/j.ejrad.2020.108991
Dinapoli, N. et al. Magnetic resonance, vendor-independent, intensity histogram analysis predicting pathologic complete response after radiochemotherapy of rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 102(4), 765–774 (2018).
pubmed: 29891200 doi: 10.1016/j.ijrobp.2018.04.065
Antunes, J. T. et al. Radiomic features of primary rectal cancers on baseline T2-weighted MRI are associated with pathologic complete response to neoadjuvant chemoradiation: A multisite study. J. Magn. Reson. Imaging 52(5), 1531–1541 (2020).
pubmed: 32216127 pmcid: 7529659 doi: 10.1002/jmri.27140
Cusumano, D. et al. Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer. Radiol. Med. (Torino) 123(4), 286–295 (2018).
doi: 10.1007/s11547-017-0838-3
Caruso, D. et al. Haralick’s texture features for the prediction of response to therapy in colorectal cancer: A preliminary study. Radiol. Med. (Torino) 123(3), 161–167 (2018).
doi: 10.1007/s11547-017-0833-8
Petkovska, I. et al. Clinical utility of radiomics at baseline rectal MRI to predict complete response of rectal cancer after chemoradiation therapy. Abdom. Radiol. 45(11), 3608–3617 (2020).
doi: 10.1007/s00261-020-02502-w
Petresc, B. et al. Pre-treatment T2-WI based radiomics features for prediction of locally advanced rectal cancer non-response to neoadjuvant chemoradiotherapy: A preliminary study. Cancers 12(7), 1894 (2020).
pmcid: 7409205 doi: 10.3390/cancers12071894
De Cecco, C. N. et al. Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: Initial experience. Abdom. Radiol. 41(9), 1728–1735 (2016).
doi: 10.1007/s00261-016-0733-8
Zhou, X. et al. Radiomics-based pretherapeutic prediction of non-response to neoadjuvant therapy in locally advanced rectal cancer. Ann. Surg. Oncol. 26(6), 1676–1684 (2019).
pubmed: 30887373 pmcid: 6510882 doi: 10.1245/s10434-019-07300-3
Giannini, V. et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18 F-FDG PET and MRI radiomics features. Eur. J. Nucl. Med. Mol. Imaging 46(4), 878–888 (2019).
pubmed: 30637502 doi: 10.1007/s00259-018-4250-6
Nie, K. et al. Rectal cancer: Assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI. Clin. Cancer Res. 22(21), 5256–5264 (2016).
pubmed: 27185368 doi: 10.1158/1078-0432.CCR-15-2997
Cheng, Y. et al. Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer. Abdom. Radiol. 46(11), 5072–5085 (2021).
doi: 10.1007/s00261-021-03219-0
Chee, C. G. et al. CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: A potential imaging biomarker for treatment response and prognosis. PLoS One 12(8), e0182883 (2017).
pubmed: 28797063 pmcid: 5552251 doi: 10.1371/journal.pone.0182883
Bibault, J.-E. et al. Deep learning and radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer. Sci. Rep. 8(1), 1–8 (2018).
Bang, J.-I. et al. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [18 F] FDG PET/CT scans in locally advanced rectal cancer. Eur. J. Nucl. Med. Mol. Imaging 43(3), 422–431 (2016).
pubmed: 26338180 doi: 10.1007/s00259-015-3180-9
Van Helden, E. et al. Radiomics analysis of pre-treatment [18F] FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment. Eur. J. Nucl. Med. Mol. Imaging 45(13), 2307–2317 (2018).
pubmed: 30094460 pmcid: 6208805 doi: 10.1007/s00259-018-4100-6
Li, Z.-Y. et al. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer. World J. Gastroenterol. 26(19), 2388 (2020).
pubmed: 32476800 pmcid: 7243642 doi: 10.3748/wjg.v26.i19.2388
Shahzadi, I. et al. Do we need complex image features to personalize treatment of patients with locally advanced rectal cancer? In International Conference on Medical Image Computing and Computer-Assisted Intervention. (Springer, 2021).
Chidambaram, V. et al. Investigation of volumetric apparent diffusion coefficient histogram analysis for assessing complete response and clinical outcomes following pre-operative chemoradiation treatment for rectal carcinoma. Abdom. Radiol. 42(5), 1310–1318 (2017).
doi: 10.1007/s00261-016-1010-6
Coppola, F. et al. The heterogeneity of skewness in T2W-based radiomics predicts the response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Diagnostics 11(5), 795 (2021).
pubmed: 33924854 pmcid: 8146691 doi: 10.3390/diagnostics11050795
Cheng, Y. et al. Multiparametric MRI-based radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer. Abdom. Radiol. 46, 1–14 (2021).
doi: 10.1007/s00261-021-03219-0
Pizzi, A. D. et al. MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal cancer. Sci. Rep. 11(1), 1–11 (2021).
Dworak, O., Keilholz, L. & Hoffmann, A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis. 12(1), 19–23 (1997).
pubmed: 9112145 doi: 10.1007/s003840050072
Canny, J. A computational approach to edge detection. IEEE Trans. Pattern Anal. Mach. Intell. 6, 679–698 (1986).
doi: 10.1109/TPAMI.1986.4767851
Tustison, N. J. et al. N4ITK: Improved N3 bias correction. IEEE Trans. Med. Imaging 29(6), 1310–1320 (2010).
pubmed: 20378467 pmcid: 3071855 doi: 10.1109/TMI.2010.2046908
Alex Zwanenburg, S. L., Sebastian, S. Medical Image Radiomics Processor.
Zwanenburg, A. et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295(2), 328–338 (2020).
pubmed: 32154773 doi: 10.1148/radiol.2020191145
Depeursinge, A. et al. Standardised Convolutional Filtering for Radiomics. arXiv preprint arXiv:2006.05470 (2020).
Zwanenburg, A. et al. Assessing robustness of radiomic features by image perturbation. Sci. Rep. 9(1), 1–10 (2019).
doi: 10.1038/s41598-018-36938-4
Peng, H., Long, F. & Ding, C. Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans. Pattern Anal. Mach. Intell. 27(8), 1226–1238 (2005).
pubmed: 16119262 doi: 10.1109/TPAMI.2005.159
Gel’fand, I. M. & Yaglom, A. M. Computation of the amount of information about a stochastic function contained in another such function. Uspekhi Matematicheskikh Nauk 12(1), 3–52 (1957).
Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. J. R. Stat. Soc. Ser. B Stat. Methodol. 67(2), 301–320 (2005).
doi: 10.1111/j.1467-9868.2005.00503.x
Efron, B. & Hastie, T. Computer Age Statistical Inference. vol. 5. (Cambridge University Press, 2016).
Hothorn, T. & Lausen, B. On the exact distribution of maximally selected rank statistics. Comput. Stat. Data Anal. 43(2), 121–137 (2003).
doi: 10.1016/S0167-9473(02)00225-6
Hosmer, D. W. & Lemesbow, S. Goodness of fit tests for the multiple logistic regression model. Commun. Stat. Theory Methods 9(10), 1043–1069 (1980).
doi: 10.1080/03610928008827941
Demler, O. V., Paynter, N. P. & Cook, N. R. Tests of calibration and goodness-of-fit in the survival setting. Stat. Med. 34(10), 1659–1680 (2015).
pubmed: 25684707 pmcid: 4555993 doi: 10.1002/sim.6428
Zhuang, Z. et al. Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer. J. Transl. Med. 19(1), 1–10 (2021).
doi: 10.1186/s12967-021-02919-x
Li, M. et al. Radiomics of rectal cancer for predicting distant metastasis and overall survival. World J. Gastroenterol. 26(33), 5008 (2020).
pubmed: 32952346 pmcid: 7476170 doi: 10.3748/wjg.v26.i33.5008
Boldrini, L. et al. Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): A hypothesis-generating study for an innovative personalized medicine approach. Radiol. Med. (Torino) 124(2), 145–153 (2019).
doi: 10.1007/s11547-018-0951-y
Jeon, S. H. et al. Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer. Radiat. Oncol. 14(1), 1–10 (2019).
doi: 10.1186/s13014-019-1246-8
Aker, M. et al. Magnetic resonance texture analysis in identifying complete pathological response to neoadjuvant treatment in locally advanced rectal cancer. Dis. Colon Rectum 62(2), 163–170 (2019).
pubmed: 30451764 doi: 10.1097/DCR.0000000000001224
Li, Z. et al. Evaluating treatment response to neoadjuvant chemoradiotherapy in rectal cancer using various MRI-based radiomics models. BMC Med. Imaging 21(1), 1–10 (2021).
doi: 10.1186/s12880-021-00560-0
Bulens, P. et al. Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics. Radiother. Oncol. 142, 246–252 (2020).
pubmed: 31431368 doi: 10.1016/j.radonc.2019.07.033
Liu, Z. et al. Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clin. Cancer Res. 23(23), 7253–7262 (2017).
pubmed: 28939744 doi: 10.1158/1078-0432.CCR-17-1038
van Griethuysen, J. J. et al. Radiomics performs comparable to morphologic assessment by expert radiologists for prediction of response to neoadjuvant chemoradiotherapy on baseline staging MRI in rectal cancer. Abdom. Radiol. 45(3), 632–643 (2020).
doi: 10.1007/s00261-019-02321-8
Yi, X. et al. MRI-based radiomics predicts tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Front. Oncol. 9, 552 (2019).
pubmed: 31293979 pmcid: 6606732 doi: 10.3389/fonc.2019.00552
Yuan, Z. et al. CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study. J. Med. Imaging Radiat. Oncol. 64(3), 444–449 (2020).
pubmed: 32386109 doi: 10.1111/1754-9485.13044
Shaish, H. et al. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: An international multicenter study. Eur. Radiol. 30(11), 6263–6273 (2020).
pubmed: 32500192 doi: 10.1007/s00330-020-06968-6
Hamerla, G. et al. Radiomics model based on non-contrast CT shows no predictive power for complete pathological response in locally advanced rectal cancer. Cancers 11(11), 1680 (2019).
pmcid: 6895820 doi: 10.3390/cancers11111680
Crimì, F. et al. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC). Radiol. Med. (Torino) 125(12), 1216–1224 (2020).
doi: 10.1007/s11547-020-01215-w
Rao, S.-X. et al. CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy?. United Eur. Gastroenterol. J. 4(2), 257–263 (2016).
doi: 10.1177/2050640615601603
Ferrari, R. et al. MR-based artificial intelligence model to assess response to therapy in locally advanced rectal cancer. Eur. J. Radiol. 118, 1–9 (2019).
pubmed: 31439226 doi: 10.1016/j.ejrad.2019.06.013
Zhang, Y. et al. A Novel multimodal radiomics model for preoperative prediction of lymphovascular invasion in rectal cancer. Front. Oncol. 10, 457 (2020).
pubmed: 32328460 pmcid: 7160379 doi: 10.3389/fonc.2020.00457
Chiloiro, G. et al. Delta radiomics can predict distant metastasis in locally advanced rectal cancer: The challenge to personalize the cure. Front. Oncol. 10, 2680 (2020).
doi: 10.3389/fonc.2020.595012
Horvat, N. et al. MRI of rectal cancer: Tumor staging, imaging techniques, and management. Radiographics 39(2), 367–387 (2019).
pubmed: 30768361 doi: 10.1148/rg.2019180114
Cusumano, D. et al. A field strength independent MR radiomics model to predict pathological complete response in locally advanced rectal cancer. Radiol. Med. (Torino) 126(3), 421–429 (2021).
doi: 10.1007/s11547-020-01266-z
De Cecco, C. N. et al. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance. Investig. Radiol. 50(4), 239–245 (2015).
doi: 10.1097/RLI.0000000000000116
Meng, Y. et al. Novel radiomic signature as a prognostic biomarker for locally advanced rectal cancer. J. Magn. Reson. Imaging 48(3), 605–614 (2018).
doi: 10.1002/jmri.25968
Cui, Y. et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur. Radiol. 29(3), 1211–1220 (2019).
pubmed: 30128616 doi: 10.1007/s00330-018-5683-9

Auteurs

Iram Shahzadi (I)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
German Cancer Consortium (DKTK) partner site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Alex Zwanenburg (A)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
German Cancer Consortium (DKTK) partner site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.

Annika Lattermann (A)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
German Cancer Consortium (DKTK) partner site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Annett Linge (A)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
German Cancer Consortium (DKTK) partner site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Christian Baldus (C)

Department of Radiology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Jan C Peeken (JC)

German Cancer Consortium (DKTK) partner site Munich, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, München, Germany.
Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Neuherberg, Germany.

Stephanie E Combs (SE)

German Cancer Consortium (DKTK) partner site Munich, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, München, Germany.
Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Neuherberg, Germany.

Markus Diefenhardt (M)

Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Frankfurt am Main, Germany.
German Cancer Consortium (DKTK) partner site Frankfurt, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Frankfurt Cancer Institute, Frankfurt, Germany.

Claus Rödel (C)

Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Frankfurt am Main, Germany.
German Cancer Consortium (DKTK) partner site Frankfurt, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Frankfurt Cancer Institute, Frankfurt, Germany.

Simon Kirste (S)

Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK) partner site Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Anca-Ligia Grosu (AL)

Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK) partner site Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Michael Baumann (M)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Mechthild Krause (M)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
German Cancer Consortium (DKTK) partner site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, Germany.

Esther G C Troost (EGC)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
German Cancer Consortium (DKTK) partner site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, Germany.

Steffen Löck (S)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. steffen.loeck@oncoray.de.
German Cancer Consortium (DKTK) partner site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany. steffen.loeck@oncoray.de.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. steffen.loeck@oncoray.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Radiothérapie › Chimioradiothérapie › Analysis of MRI and CT-based radiomics...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Analysis of MRI and CT-based radiomics...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Analysis of MRI and CT-based radiomics...
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Traitement néoadjuvant › Analysis of MRI and CT-based radiomics...
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine de précision › Analysis of MRI and CT-based radiomics...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Tumeurs du rectum › Analysis of MRI and CT-based radiomics...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Reproductibilité des résultats › Analysis of MRI and CT-based radiomics...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Analysis of MRI and CT-based radiomics...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Tomographie à rayons X › Tomodensitométrie › Analysis of MRI and CT-based radiomics...